This study aims to evaluate the feasibility of incorporating BRCA1/2 testing into breast cancer screening in China by comparing the cost-effectiveness of three strategies: symptom-based screening alone (Symptom-only strategy), population-based BRCA1/2 testing (population-based strategy), and family-history-based BRCA1/2 testing (FH-based strategy). The gene discussed is BRCA1; the disease is breast carcinoma.